HIGHLIGHTS
SUMMARY
In agreement with this hypothesis, clinical trials showed that patients with high TMB values had a better response and outcome as compared with patients with low TMB, when treated with single agent or combination of PD-L1 and CTLA inhibitors. While these findings demonstrate an increasing interest in the assessment of TMB across different tumor types, TMB testing is far from being standardized. TMB quantification with targeted next generation sequencing (NGS) panels has been shown to correlate with WES-derived TMB and to associate with ICI response, making the clinical assessment of TMB practically . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.